Gilead Sciences Gets Initial OK On $247M HIV Antitrust Deal - Law360

Gilead Sciences Gets Initial OK On $247M HIV Antitrust Deal – Law360

Source Node: 2284411
By Bonnie Eslinger (September 21, 2023, 9:34 PM EDT) — A California federal judge on Thursday granted preliminary approval to Gilead’s deal to pay the direct purchasers of its HIV medications $246.8 million to end claims the pharmaceutical company cut a deal with Teva to delay generic versions, saying considering the litigation risks, “the settlement is a reasonable one.”…

Time Stamp:

More from Law 360